Alternative to Alimta Coming for Mesothelioma Patients
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company….
The post Alternative to Alimta Coming for Mesothelioma Patients appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
FDA Moves Closer to Standardized Testing for Asbestos in Talc
The U.S. Food and Drug Administration moved closer on Tuesday to formulating standardized testing of talc-based products for the presence of toxic asbestos fibers. Experts from eight different federal agencies explained earlier recommendations at a day-long hearing. The session also featured input from 25 members of the public, which included industry representatives, consumer advocates and…
The post FDA Moves Closer to Standardized Testing for Asbestos in Talc appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
Duke Completes Largest Study of Mesothelioma in Women
Women diagnosed with peritoneal mesothelioma were 10 years younger on average than those with pleural mesothelioma in a recent case study at the Duke University Medical Center. It was the largest study of women with mesothelioma at a single institution that included histopathology, survival, exposure, demographics and objective markers (asbestosis, fiber analysis and parietal pleural…
The post Duke Completes Largest Study of Mesothelioma in Women appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
Mesothelioma Deaths Peak 30 Years After Asbestos Ban
Almost 30 years after Italy passed sweeping legislation that banned the mining, use and commercialization of asbestos, the country is facing the peak of its mesothelioma cancer crisis. The worst has just arrived. Asbestos may be the primary cause of mesothelioma, but banning it did not slow the rate of diagnosis or death from this…
The post Mesothelioma Deaths Peak 30 Years After Asbestos Ban appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
ONCOS-102 Shows Promise in Combination Mesothelioma Treatment
ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving…
The post ONCOS-102 Shows Promise in Combination Mesothelioma Treatment appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
FDA Panel Recommends Standardized Talc Testing for Asbestos
A team of experts from eight different federal agencies has presented the U.S. Food and Drug Administration with preliminary recommendations to standardize the testing of talc for the presence of asbestos and other potentially harmful mineral products. The recommendations, some of which reject long-held talc industry positions, are designed to end the discrepancies in analysis…
The post FDA Panel Recommends Standardized Talc Testing for Asbestos appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
Study Uncovers Drug Combination for Sarcomatoid Mesothelioma
Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the…
The post Study Uncovers Drug Combination for Sarcomatoid Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
Researchers Find Potential New Target for Mesothelioma Treatment
An international research team has identified a novel molecular target with potential to significantly improve future treatment of malignant pleural mesothelioma. The recent findings could lead to a drug that targets key genetic inhibitors often preventing a patient’s own immune system from suppressing mesothelioma tumor growth. Dr. Antonio Giordano, part of the collaborative research team,…
The post Researchers Find Potential New Target for Mesothelioma Treatment appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
Pleural and Peritoneal Mesothelioma Combination Can Be Managed
A patient diagnosed with pleural and peritoneal mesothelioma today can survive well beyond expectations, provided personalized treatment can be found at a specialty center. Research from the Columbia University Medical Center in New York City has shown that despite the poor prognosis typically accompanies this rare diagnosis, patients still can thrive. “This is an understudied,…
The post Pleural and Peritoneal Mesothelioma Combination Can Be Managed appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.